Evofem Biosciences, Inc.
EVFM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 471% | -88.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 84.4% | 56.8% | 78.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | -$0 |
| % Margin | – | -25.9% | 38.7% | -14.1% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | -37% | 113.1% | -42.8% |
| EPS | -0.01 | -0.015 | 0.008 | -0.032 |
| % Growth | 35.1% | -283.3% | 126.7% | – |
| EPS Diluted | -0.01 | -0.015 | 0 | -0.032 |
| Weighted Avg Shares Out | 0 | 0 | 6 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 6 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | – | -23.1% | 65.8% | -9% |